| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) financing activities | -394 | 3,277 |
| Effect of exchange rate changes on cash and cash equivalents | 2,263 | 1,972 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -106,647 | -81,132 |
| Cash and cash equivalents at beginning of period | 389,195 | - |
| Cash and cash equivalents at end of period | 282,548 | - |
Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. (PCVX)